Clinical trial · Observational
Prognostic Value of Stem Cell Related Markers
Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II
NCT01265225CI-TRIAL-00013228withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no finance
Summary
Brief summary (as posted)
The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ductal Carcinoma in Situ * DCIS + Microinvasion stages 1 or 11 without positive lymph nodes Exclusion Criteria: * tumor specimen with higher than grade II * BRACA 1 or BRACA 2 mutation * Neoadjuvant chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.